057 Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic DMARDs. (12th April 2019) - van Vollenhoven, R; Dore, R; Chen, K; Camp, H S; Enejosa, J; Shaw, T; Suboticki, J L; Hall, S